Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 17/20 | 0.59 |
| ▸ | THRB | P10828 | 17/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23441663 | 0.96 | THRA (0.57) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL23442818 | 0.96 | THRA (0.57) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL30075027 | 0.96 | THRA (0.56) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL23442834 | 0.90 | THRA (0.69) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632378 | 0.86 | THRA (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL23442814 | 0.86 | THRA (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL30075059 | 0.86 | THRA (0.66) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL24032555 | 0.85 | THRA (0.55) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL23441953 | 0.85 | THRA (0.60) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL23442829 | 0.84 | THRB (0.69) | THRATHRBCYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113454069-B | 1,2, 4-Triazine-3, 5-dione compound, and preparation method and application thereof | 昆药集团股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20230089582-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KPC PHARMACEUTICALS INC (CN) | 2023-03-23 | — | — | US | disclosed |
| EP-4083024-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KPC Pharmaceuticals, Inc. (CN) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089582-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885CYP2C9 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.